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doi:10.1016/j.jfma.2011.08.021Background/Purpose: Taiwan is only now beginning to offer palliative care to patients who do
not have cancer. This study aimed to document the polysymptomatic presentation of illness in
Taiwanese patients with late-stage nonmalignant disease and to evaluate the potential bene-
fits of palliative care for these patients. The results may help to educate healthcare personnel
regarding the need for and importance of palliative treatment as comprehensive, appropriate
end-of-life care for patients with nonmalignant disease.
Methods: We retrospectively analyzed 115 patients without cancer hospitalized in a community
hospital in Taiwan: 61 had organic brain disease, 31 had chronic obstructive pulmonary
disease, 17 had chronic renal failure, 14 had congestive heart failure, 12 had liver cirrhosis,
and 20 had multiple illnesses. The median age was 81 years (interquartile range 69e86 years),
and 51% of patients were enrolled from intensive care. Symptoms and their severity wereHematology-Oncology, Chang Gung Memorial Hospital, 5 Fuxing Street, Guishan Township, Taoyuan
o.com.tw (W.-C. Chou).
ight ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.
Palliative care for nonmalignant disease in Taiwan 407analyzed. Patients’ and their families’ understanding of the diagnosis and prognosis and “Do
Not Resuscitate” (DNR) consent were evaluated pre- and post-palliative care.
Results: The four leading symptoms were fatigue (96%), fever (86%), cough (81%), and dyspnea
(79%). No significant differences in symptom prevalence were found between different sexes,
ages, performance statuses, ward locations, or underlying diseases, except for fewer episodes
of dizziness, more frequent episodes of cough in patients older than 80 years, and more
episodes of jaundice in ward service subjects. Only the presence of abdominal distension
differed significantly between surviving and deceased patients (22.9% vs. 40.3%; pZ 0.004).
After the start of palliative care, patients’ DNR consent increased (105/115 before, 114/115
after). Patients’ recognition of the diagnosis and prognosis increased from 13 to 64, respec-
tively, with a simultaneous increase in family members’ recognition (66 before, 114 after).
Conclusion: Hospice care with good symptom control is warranted for patients with late-stage
nonmalignant disease who need appropriate end-of-life care. Medical personnel need educa-
tion in the importance of palliative care and the identification of patients who could benefit
from it. In addition, patients should be informed of its availability.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Given the aging of the human population worldwide, since
the early 2000s, more people have died annually of chronic
disease than of cancer, and they require symptom and pain
management as they approach the end of life. Palliative
care requirements for patients with cancer and nonmalig-
nant diseases are similar.1,2 Palliative care may have an
important role in treating patients with congestive heart
failure, chronic obstructive pulmonary disease, and chronic
renal failure.3e5 In the United States, for example, the
majority of patients receiving palliative care have nonma-
lignant disease.6
Palliative care became popular in Taiwan after it was
introduced in 1990, but at that time it was applied primarily
to cancer patients.7 Patients with nonmalignant diseases
were rarely candidates for palliative care, in part because
of lack of insurance coverage, until September 2009, when
the national health insurance regulations changed and
coverage was finally provided for palliative care for non-
cancer patients.
Knowledge of the prevalence of common end-of-life
symptoms is necessary to identify patients’ needs for
symptom control and planning of palliative care. Weakness,
pain, anorexia, and cachexia are the most common symp-
toms in terminal cancer patients in Taiwan.8 However,
although studies in other countries have reported charac-
teristic symptoms for end-stage nonmalignant chronic
disease, similar studies demonstrating these symptoms are
lacking in Taiwan. Nevertheless, it is recognized that in
both cancer patients and noncancer patients, most symp-
toms become increasingly difficult to control and progres-
sively worsen closer to death. Early identification of the
most prevalent end-of-life symptoms is necessary for early
intervention and treatment planning, including possible
referral to palliative care. Data regarding the patterns and
prevalence of distressing end-of-life symptoms in patients
with nonmalignant disease are not yet available in Taiwan;
therefore, the present study is intended as an initial
contribution to the collection of such data.
Knowledge of the prevalence of common late-stage
symptoms, along with a greater awareness of thepalliative care concept on the part of medical personnel,
patients, and their families, may help to identify patients
with nonmalignant disease who could benefit from pallia-
tive care. We retrospectively analyzed the prevalence of
common symptoms in patients with life-threatening
nonmalignant disease receiving palliative care in a commu-
nity hospital in Taiwan that is the first institution in the
country to provide such care on a nonprofit basis for this
patient group. Our aim was to document the poly-
symptomatic presentation of illness in Taiwanese patients
with late-stage nonmalignant disease and to evaluate the
potential benefits of palliative care for these patients. The
results may be useful in educating healthcare personnel
regarding the capabilities and availability of palliative
treatment for patients without cancer who need compre-
hensive and appropriate end-of-life care.Methods
Patient selection
The 115 patients in this study were selected consecutively
from those admitted to Saint Paul’s Hospital who received
care from the hospital’s palliative care team from
September 2007 through December 2009. Saint Paul’s
Hospital is an acute-care general hospital with 550 beds; it
provides specialist palliative care service for 5e12 patients
on a daily basis. There was no underlying assumption
regarding the size of the sample.
Criteria for inclusion were related to diagnosis, referral
source, and agreement with the care plan. Patients were
required to be diagnosed with one (or more) of five chronic
diseasesdorganic brain disease (OBD), defined as cere-
brovascular accident with sequelae, hypoxemic encepha-
lopathy, cerebral palsy, parkinsonism, or dementia; chronic
obstructive pulmonary disease (COPD); congestive heart
failure (CHF); decompensated cirrhosis of the liver (DLC);
and chronic renal failure in uremic stage (CRF)dor multiple
diseases, defined as a co-occurrence of at least two of the
five chronic diseases, along with admission to the hospital
because of an acute exacerbation of the underlying chronic
408 Y.-S. Hung et al.illness or an acute episode of infection, gastrointestinal
bleeding, or shock. End-stage disease was defined as
a combination of a long-term history of one of the five
chronic diseases and the presence of distressing uncon-
trolled symptoms recognized clinically as leading to the
terminal common pathway.
The five chronic illnesses were chosen based on the
leading causes of death in Taiwan, excluding accidents,
suicide, and acute illness. During the study period, a total of
464 patients died at Saint Paul’s Hospital, 188 of whom had
one or more of the five chronic illnesses, making the cover
rate before death 55/188. Among the remaining patients
with thefive chronic illnesses, 133 patientswerenot referred
to palliative care for several reasons, including: the primary
physician determining it unnecessary or death being unan-
ticipated (nZ 23), the period enrolled in palliative care
being less than 24 hours (nZ 21; an exclusion criterion for
this study); or the presence of concomitant malignant
disease (nZ 20; anexclusion criterionof this study). Another
13 patients refused combined care from their primary
physician with the palliative care team.
With regard to the second criterion, patients were either
referred by primary care physicians or actively recruited by
the palliative care team if a “Do Not Resuscitate” (DNR)
consent form had been signed after hospitalization. To
meet the third criterion, patients and their family had to
agree to combine care from the primary physician and the
palliative care team. To ensure adequate time to assess
patients’ distressing symptoms, any patient with a lifespan
of less than 24 hours after referral was excluded from the
study. Patients diagnosed with malignancies were also
excluded. We did not recruit a control group of patients
who did not receive palliative care.Hospice setting and data collection
The 115 participants were under the combined care of
a primary care physician and a multidisciplinary palliative
care team consisting of physicians, specialist nurses, social
workers, Christian (Roman Catholic) chaplains, and volun-
teers. Team meetings were held every 1e2 weeks.
The study data consisted of patients’ demographic data
[age, gender, Eastern Cooperative Oncology Group (ECOG)
performance statuses, underlying diseases, and survival
times], and the patients’ assessed distressing symptoms.
Patients’ symptoms were recorded immediately after the
patients were referred to palliative care and were all
recorded by the same specialist nurse using a formulated
“Symptoms Record” form. Patients’ symptoms were then
recorded daily by the same specialist nurse who had initially
evaluated them, who recorded the presence or absence of
symptoms using a list of 29 common symptoms. These
symptoms were chosen on the basis of our clinical experi-
ence and previously published studies involving patients
with either cancer or terminal nonmalignant disease.9e11
Severity scores were determined for the different
symptoms by the specialist nurse when the symptoms were
being recorded. A five-stage scoring system was used in
which 0 represented no symptoms; 1 represented mild
symptoms presenting occasionally without causing discom-
fort; 2 represented moderate symptoms that might causepatient discomfort; 3 represented severe symptoms
occurring frequently and limiting activities; and 4 repre-
sented extreme severity that persisted and could not be
tolerated by the patient. The primary caregiver answered
questions as far as possible when patients were unable to
communicate.
All patients were followed until death or until the study
conclusiondJune 30, 2010. The study was approved by the
ethics committee of Saint Paul’s Hospital.Statistical analysis
Statistical analyses were performed using SPSS 15.0 statis-
tics software (SPSS Inc, Chicago, IL, USA). Basic demo-
graphic data were summarized as n (%) for categorical
variables and median with interquartile range (IQR; Q1eQ3)
for continuous variables. Furthermore, the prevalence of
clinical symptoms was tabulated as n (%) by demographics,
and compared using the Pearson chi-square test, or the
Fisher’s exact test if the number in any cell was less than 5.
All statistical assessments were considered significant when
p< 0.05.Results
Data from 115 patients were analyzed in this study. Their
basic demographic data are summarized in Table 1. There
were 63 males (55%) and 52 females (45%), with a median
age of 81 years (IQR 69e86 years). Half the patients (51%)
were enrolled from the intensive care unit (ICU). The
median time from admission date to referral was 8 days
(IQR 3e15 days). Seventy-seven per cent had an ECOG
performance status of Grade 4. The underlying diseases
were observed as 61 (53%) cases of OBD, 31 (27%) of COPD,
17 (14.8%) of CRF, 14 (12.2%) of CHF, and 12 (10.4%) of DLC.
In addition, 20 patients (17.4%) were diagnosed with
multiple diseases. At the last follow-up, 48 (41.7%) of the
115 subjects had survived, and the median palliative care
time was observed to be 19 days (IQR 5e93 days).
The number of symptoms and their prevalence are
summarized in Table 2. The primary cause of fever in this
study was infection due to acute exacerbation or compli-
cations of the underlying disease. The prevalence of pain in
our palliative care patients was 20%. Seizures were present
in 16% of patients. Patients who survived has a lower rate of
abdominal distension (22.9%) compared with those who
died (49.3%) (pZ 0.004); these results are shown sepa-
rately in Table 2 for surviving and deceased patients.
However, no significant differences were found in other
symptoms between survivors and those who died.
There was no difference in the prevalence of most
symptoms when measured according to sex, performance
status, age, and ward service. The overall prevalence of
clinical symptoms greater than 50% was derived as 95.7%
(110/115) with fatigue, 86.1% (99/115) with fever, 80.9%
(93/115) with cough, 79.1% (91/19) with dyspnea, 61.7%
(71/115) with edema, and 61.7% (71/115) with anemia. It
was found that the prevalence of cough and dizziness were
significantly different between patients younger than age
80 and 80 years or older. Furthermore, the prevalence of
Table 1 Subjects’ basic demographic data (nZ 115).
Variable (nZ 115)
Sexa
Male 63 (54.8)
Female 52 (45.2)
Age (y)b 81 (69e86)
< 70 (nZ 29) 55 (47.5e66.0)
70e79 (nZ 19) 75 (72e76)
80e89 (nZ 50) 84 (81.7e86.0)
> 90 (nZ 17) 91 (90.5e95.0)
Patients’ inpatient locationa
Ward 56 (48.7)
Intensive care unit 59 (51.3)
Enrollment condition
Physician referral 10 (8.7)
Post-DNR status 105 (91.3)
ECOG performance statusa
Grade 1 1 (0.9)
Grade 2 2 (1.7)
Grade 3 23 (20.0)
Grade 4 89 (77.4)
Underlying diseasea
Organic brain lesion 47 (40.9)
Chronic obstructive pulmonary disease 24 (20.9)
Liver cirrhosis 10 (8.7)
Chronic renal failure 8 (7.0)
Congestive heart failure 6 (5.2)
Multiple diseases 20 (17.4)
Median from admission to referralb (d) 8 (3e15)
Number of survivors at last follow-upa 48 (41.7)
Median total palliative careb (d) 19 (5e93)
DNRZ Do Not Resuscitate; ECOGZ Eastern Cooperative
Oncology Group.
a Data were summarized as n (%) for categorical data and
median (interquartile range, Q1eQ3).
b Data were summarized as n (%) for continuous data.
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ward patients versus those in the ICU.
The statistical analysis of the severity of symptoms at
admission is shown in Table 3. Severity was determined for
the different symptoms by the specialist nurse using a five-
stage scoring system (0e5 as described in Methods). The
symptoms are listed according to severity, with fatigue,
fever, cough, and dyspnea at the top of the list as most
severe and most frequent, followed by less severe and less
frequent symptoms. Of all the symptoms, only abdominal
distension is shown separately for surviving and deceased
patients since this was the only symptom that showed
significant differences between patients who survived and
those who died during the study.
The prevalence and severity of symptoms in the various
diseases is summarized in Table 4. Fatigue was a common
symptom in all disease categories. Fever and cough were
frequent in every disease except liver cirrhosis. A higher
percentage of patients with DLC had anemia, gastrointes-
tinal bleeding, abdominal discomfort, pain, jaundice, and
ascites; however, this result was not statistically significant
when compared with other disease entities. The subjectswith organic brain lesions may have a lower prevalence of
clinical symptoms of edema, anemia, mental disturbance,
abdominal distension, anorexia, pain, nausea, jaundice,
insomnia, and ascites, whereas those with COPD may have
a higher prevalence of cough, dyspnea, mental distur-
bance, anorexia, and insomnia. Patients with DLC may have
a lower prevalence of cough, and dyspnea, but a higher
prevalence of anemia, gastrointestinal bleeding, abdominal
distension, pain, and nausea. Those with CRF may have
a higher prevalence of edema and dyspnea, but a lower
prevalence of pruritus. Fifty-five (47.8%) patients had death
listed as the reason for discharge. The median survival time
after referral to the palliative care team was 37 days (95%
CI 0e86 days). The 6 months’ survival rate was 37.6%
(Fig. 1).
Palliative care was shown to benefit patients and their
families (Table 5). The ratio of patients who signed DNR
forms increased from before to after the start of palliative
care, from 105/115 to 114/115, respectively. More
patients were also able to recognize their diagnosis and
prognosis. The number of patients increased from 13 to 64
for those understanding their diagnosis, and from 10 to 25
for those understanding their prognosis. A simultaneous
increase was recorded in patients’ family members
recognizing diagnosis and prognosis (before 66, after 114).
No patients received cardiopulmonary resuscitation,
intubation, or cardiac massage after their enrollment in
palliative care.Discussion
The distribution of the diagnoses of nonmalignant disease in
this studywas similar to that of the leading noncancer causes
of death in Taiwan in 2006.12 This study confirmed that
patients with late-stage nonmalignant disease are poly-
symptomatic in the same manner as cancer patients. The
prevalence of most symptoms closely resembled those of
patients with terminal cancer published in previous reports.8
No statistically significant differences were observed in the
prevalence of most symptoms when sex, age, performance
status, care setting, and underlying disease were compared.
The terminal common pathways were similar between
cancer and nonmalignant disease.13,14
Fatigue was the most frequent symptom in this study
and is one of the most common symptoms reported in
palliative care patients.11 In our study, there was a 96%
prevalence of fatigue for all patients, which is quite similar
to published studies reporting an 84% prevalence in a study
of 1000 patients with advanced cancer, 11 and a 99% prev-
alence in patients following radiotherapy or chemo-
therapy.15 In nonmalignant conditions, fatigue was
reported in 96% of patients with COPD16 and in 82% of those
with heart failure.17 Some observers therefore maintain
that fatigue in cancer patients as well as in patients with
nonmalignant disease is underrecognized, underassessed,
and undertreated.18
Fever was the second most common symptom in this
study. Wachtel et al reported a 35% prevalence of fever in
end-stage cancer patients.13 Fever in cancer patients is
generally associated with infection, treatment-related
myelosuppression, and complications of a procedure or
Table 2 Prevalence of patients’ clinical symptoms.
Symptoms Total Age Sex Inpatient location COG status Last follow-up outcome
(nZ 115) < 80 y  80 y Males Females Ward Intensive
care unit
Grade 1e3 Grade 4 Dead Survivors
(nZ 48) (nZ 67) (nZ 63) (nZ52) (nZ 56) (nZ 59) (nZ 2 (nZ 89) (nZ 67) (nZ 48)
Fatigue 110 (95.7) 46 (95.8) 64 (95.5) 61 (96.8) 49 (94.2) 55 (98.2) 55 (93.2) 25 (96 ) 85 (95.5) 65 (97.0) 45 (93.8)
Fever 99 (86.1) 44 (91.7) 55 (82.1) 55 (87.3) 44 (84.6) 46 (82.1) 53 (89.8) 23 (88 ) 76 (85.4) 55 (85.9) 41 (85.4)
Cough 93 (80.9) 34 (70.8) 59 (88.1)** 53 (84.1) 40 (76.9) 43 (76.8) 50 (84.7) 21 (80 ) 72 (80.9) 52 (77.6) 41 (85.4)
Dyspnea 91 (79.1) 35 (72.9) 56 (83.6) 52 (82.5) 39 (75.0) 41 (73.2) 50 (84.7) 19 (73 ) 72 (73.1) 52 (77.6) 39 (81.3)
Edema 71 (61.7) 26 (54.2) 45 (67.2) 38 (60.3) 33 (63.5) 33 (58.9) 38 (64.4) 14 (53 ) 57 (64.0) 43 (64.2) 28 (58.3)
Anemia 71 (61.7) 31 (64.6) 40 (59.7) 36 (57.1) 35 (67.3) 32 (57.1) 39 (66.1) 19 (73 ) 52 (58.4) 45 (67.2) 26 (54.2)
Constipation 53 (46.1) 22 (45.8) 31 (46.3) 28 (44.4) 25 (48.1) 25 (44.6) 28 (47.5) 14 (53 ) 39 (43.8) 31 (46.3) 22 (45.8)
Mental
disturbance
49 (42.6) 17 (35.4) 32 (47.8) 32 (50.8) 17 (32.7) 27 (48.2) 22 (37.3) 12 (46 ) 37 (41.6) 30 (44.8) 19 (39.6)
Gastrointestinal
bleeding
48 (41.7) 23 (47.9) 25 (37.3) 25 (39.7) 23 (44.2) 19 (33.9) 29 (49.2) 8 (30.8 40 (44.9) 31 (46.3) 17 (35.4)
Abdominal
distension
44 (38.3) 18 (37.5) 26 (38.8) 22 (34.9) 22 (42.3) 22 (39.3) 22 (37.3) 9 (34.6 35 (39.3) 33 (49.3) 11 (22.9)**
Anorexia 45 (39.1) 19 (39.6) 26 (38.8) 25 (39.7) 20 (38.5) 26 (46.4) 19 (32.2) 12 (46 ) 33 (37.1) 28 (41.8) 17 (35.4)
Pressure sore 38 (33.0) 18 (37.5) 20 (29.9) 24 (38.1) 14 (26.9) 20 (35.7) 18 (30.5) 7 (26.9 31 (34.8) 25 (37.3) 13 (27.1)
Diarrhea 29 (25.2) 13 (27.1) 16 (23.9) 16 (25.4) 13 (25.0) 14 (25.0) 15 (25.4) 6 (23.1 23 (25.8) 17 (25.4) 12 (25.0)
Pain 23 (20.0) 10 (20.8) 13 (19.4) 11 (17.5) 12 (23.1) 13 (23.2) 10 (16.9) 6 (23.1 17 (19.1) 17 (25.4) 6 (12.5)
Nausea 20 (17.4) 9 (18.8) 11 (16.4) 9 (14.3) 11 (21.2) 9 (16.1) 11 (18.6) 6 (23.1 14 (15.7) 9 (13.4) 11 (22.9)
Seizure 18 (15.7) 11 (22.9) 7 (10.4) 11 (17.5) 7 (13.5) 9 (16.1) 9 (15.3) 4 (15.4 14 (15.7) 9 (13.4) 9 (18.9)
Delirium 15 (13.0) 6 (12.5) 9 (13.4) 11 (17.5) 4 (7.7) 10 (17.9) 5 (8.5) 3 (11.5 12 (13.5) 12 (17.9) 3 (6.3)
Wound 14 (12.2) 7 (14.6) 7 (10.4) 8 (12.7) 6 (11.5) 7 (12.5) 7 (11.9) 1 (3.8) 13 (14.6) 9 (13.4) 5 (10.4)
Urinary
retention
11 (9.6) 3 (6.3) 8 (12.1) 5 (7.9) 6 (11.8) 8 (14.3) 3 (5.2) 2 (7.7) 9 (10.2) 8 (11.9) 3 (6.4)
Pruritus 11 (9.6) 5 (10.4) 6 (9.0) 7 (11.1) 4 (7.7) 4 (7.1) 7 (11.9) 2 (7.7) 9 (10.2) 6 (7.0) 5 (10.4)
Jaundice 10 (8.7) 6 (12.5) 4 (6.0) 6 (9.5) 4 (7.7) 8 (14.3) 2 (3.4)* 4 (15.4 6 (6.7) 6 (9.0) 4 (8.3)
Insomnia 9 (7.8) 5 (10.4) 4 (6.0) 3 (4.8) 6 (11.5) 5 (8.9) 4 (6.8) 4 (15.4 5 (5.6) 6 (9.0) 3 (6.3)
Ascites 9 (7.8) 6 (12.5) 3 (4.5) 7 (11.1) 2 (3.8) 6 (10.7) 3 (5.1) 4 (15.4 5 (5.6) 6 (9.0) 3 (6.3)
Dizziness 8 (7.0) 7 (14.6) 1 (1.5)** 4 (6.3) 4 (7.7) 3 (5.4) 5 (8.5) 1 (3.8) 7 (7.9) 6 (9.0) 2 (4.2)
Oral ulcer 8 (7.0) 5 (10.4) 3 (4.5) 5 (7.9) 3 (5.8) 4 (7.1) 4 (6.8) 1 (3.8) 7 (7.9) 6 (9.0) 2 (4.2)
Hematuria 5 (4.3) 1 (2.1) 4 (6.0) 3 (4.8) 2 (3.8) 3 (5.4) 2 (3.4) 2 (7.7) 3 (3.4) 4 (6.0) 1 (2.1)
Dysphagia 4 (3.5) 2 (4.2) 2 (3.0) 2 (3.2) 2 (3.8) 3 (5.4) 1 (1.7) 1 (3.8) 3 (3.4) 1 (1.5) 3 (6.3)
Incontinence 2 (1.7) 0 (0) 2 (3.0) 2 (3.2) 0 (0) 2 (3.6) 0 (0) 0 (0) 2 (2.2) 1 (1.5) 1 (2.1)
Hiccups 1 (0.9) 0 (0) 1 (1.5) 1 (1.6) 0 (0) 1 (1.6) 0 (0) 1 (3.8) 0 (0) 1 (1.5) 0 (0)
Data were summarized as n (%) for each category, and compared using the Pearson chi-square test, or Fisher exact test if any numb in the cell was lower than 5.
*p< 0.05; ** p< 0.01.
ECOGZ Eastern Cooperative Oncology Group.
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Table 3 Statistical analysis of severity of symptoms at admission.
Symptom Severity
1 2 3 4
Fatigue nZ 110 29 (26.4) 50 (45.5) 25 (22.7) 6 (5.5)
Fever nZ 99 43 (43.4) 47 (47.5) 9 (9.1) 0 (0)
Cough nZ 93 21 (22.6) 57 (61.3) 15 (16.1) 0 (0)
Dyspnea nZ 91 2 (2.2) 23 (25.3) 41 (45.1) 25 (27.5)
Edema nZ 71 7 (9.9) 34 (47.9) 26 (36.6) 4 (5.6)
Constipation nZ 53 11 (20.8) 29 (54.7) 13 (24.5) 0 (0)
Mental disturbance nZ 49 2 (4.1) 19 (38.8) 21 (42.9) 7 (14.3)
Gastrointestinal bleeding nZ 48 7 (14.6) 33 (68.8) 8 (16.7) 0 (0)
Abdominal distensiona nZ 44 0 (0) 22 (50) 20 (45.5) 2 (4.5)
Deceased nZ 33 0 (0) 17 (51.5) 16 (48.5) 0 (0)
Survivors nZ 11 0 (0) 5 (45.5) 4 (36.4) 2 (18.2)
Anorexia nZ 44 2 (4.5) 28 (63.6) 13 (29.5) 1 (2.3)
Pressure soreb nZ 27 6 (22.2) 17 (63.0) 4 (14.8) 0 (0)
Diarrhea nZ 29 4 (13.8) 22 (75.9) 3 (10.3) 0 (0)
Pain nZ 23 3.91 1.31 (range 2e7)
Nausea nZ 20 4 (20.0) 14 (70.0) 2 (10.0) 0 (0)
Seizure nZ 18 3 (16.7) 8 (44.4) 7 (38.9) 0 (0)
Delirium nZ 15 3 (20) 4 (26.7) 7 (46.7) 1 (6.7)
Wound nZ 14 6 (42.9) 7 (50.0) 1 (7.1) 0 (0)
Urinary retention nZ 11 7 (63.6) 4 (36.4) 0 (0) 0 (0)
Pruritus nZ 11 0 (0) 8 (72.7) 3 (27.3) 0 (0)
Insomnia nZ 9 1 (11.1) 4 (44.4) 3 (33.3) 1 (11.1)
Ascites nZ 9 0 (0) 1 (11.1) 5 (55.6) 3 (33.3)
Dizziness nZ 8 1 (12.5) 6 (75.0) 1 (12.5) 0 (0)
Oral ulcer nZ 8 1 (12.5) 6 (75.0) 1 (12.5) 0 (0)
Hematuria nZ 5 1 (20.0) 3 (60.0) 1 (20.0) 0 (0)
Dysphagia nZ 4 0 (0) 3 (75.0) 1 (25.0) 0 (0)
Incontinence nZ 2 0 (0) 2 (100) 0 (0) 0 (0)
Hiccups nZ 1 0 (0) 1 (100) 0 (0) 0 (0)
Data were summarized as n (%) for each specific symptom except for pain, which was scored as mean standard deviation (ran-
geZminimum to maximum).
a Abdominal distension was only symptom showing a significant difference between those who were deceased and survivors in Table 2.
b Eleven subjects had missing data on pressure sores; hence, severity was recorded for only 27 subjects.
Palliative care for nonmalignant disease in Taiwan 411the cancer itself.19 The prevalence of fever in nonmalig-
nant disease is, however, not well documented in the
literature. The higher prevalence of fever in this study was
mainly attributed to sepsis, with 96% of patients docu-
mented to have had at least one infection during
hospitalization.
Cough and dyspnea were the third and fourth most
common symptoms in this study. Published studies report
a 52% prevalence of cough in cancer patients10 and an 80%,
46%, and 44% prevalence in patients with COPD, CRF, and
CHF, respectively.16,17,20 The prevalence of dyspnea has
been reported to range between 31% and 70% in cancer
patients11; 94% and 98% in patients with COPD16,21; 11% and
82% in patients with CRF20,22; and 83% and 88% in patients
with CHF.17 Edema is reported to affect 73% of patients
with CRF,20 with a 43% prevalence evident for CHF.23 The
high prevalence of cough, dyspnea, and edema in this study
is related to the underlying diseases.
The prevalence of pain is reported in the literature to be
52e84% for cancer patients11 and 21e70% for patients with
nonmalignant disease.16,20,22 The prevalence of pain was
20% in this study, which is lower than figures reported inpreviously published studies. There was a wide variation in
the prevalence of pain in our patient group: 64% of patients
with DLC had pain complaints, whereas only 4% of patients
with OBD complained of pain.We believe that the difference
is most likely due to the fact that many patients in our study
were disoriented, 43% had confused consciousness, and 13%
demonstrated deliriumdit was very difficult to evaluate the
subjective distress related to pain in disoriented patients.
Warden et al reported a PAINAD scale as a tool for caregivers
to evaluate pain in advanced dementia patients.24 Palliative
care staff, however, should recognize that pain in dis-
oriented patients is both underestimated and undertreated.
Seizure has a prevalence of 24e29% in patients with
primary or metastatic brain tumors.25,26 The prevalence of
seizure in late-stage nonmalignant disease is not known.
Eighteen patients (16%) in this study had seizure episodes,
which caused suffering to the patient and stress for the
family. Early identification of high-risk patients and avoid-
ance of precipitating factors are mandatory in the pallia-
tive care management of seizures.
Our patients’ median survival after referral to palliative
care was 37 days. Fifty-six per cent of patients died in the
Table 4 Prevalence of clinical symptoms according to disease diagnosis.
Symptom Total (nZ 115) Organic brain lesion Heart failure Chronic obstructive
pulmonary disease
Cirrhosis Renal failure Concurrent illness
No
(nZ 68)
Yes
(nZ 47)
No
(nZ 109)
Yes
(nZ 6)
No
(nZ 91)
Yes
(nZ 24)
No
(nZ 105)
Yes
(nZ 1
No
(nZ 107)
Yes
(nZ 8)
No
(nZ 95)
Yes
(nZ 20)
Fatigue 110 (95.7) 66 (97.1) 44 (93.6) 104 (95.4) 6 (100) 88 (96.7) 22 (91.7) 100 (95.2) 10 (10 102 (95.3) 8 (100) 90 (94.7) 20 (100)
Fever 99 (86.1) 56 (84.9) 40 (87.0) 93 (86.1) 3 (75) 75 (85.2) 21 (87.5) 90 (88.2) 6 (60.0 88 (84.6) 8 (100) 81 (85.3) 18 (90.0)
Cough 93 (80.9) 56 (82.4) 37 (78.7) 89 (81.7) 4 (66.7) 69 (75.8) 24 (100)* 90 (85.7) 3 (30.0 * 86 (80.4) 7 (87.5) 75 (78.9) 18 (90.0)
Dyspnea 91 (79.1) 58 (85.3) 33 (70.2) 85 (78.0) 6 (100) 68 (74.7) 23 (95.8)** 87 (82.9) 4 (40.0 85 (79.4) 6 (75.0) 72 (75.8) 19 (95.0)
Edema 71 (61.7) 50 (73.5) 21 (44.7)* 66 (60.6) 5 (83.3) 55 (60.4) 16 (66.7) 66 (62.9) 5 (50) 63 (58.9) 8 (100)* 55 (57.9) 16 (80.0)
Anemia 71 (61.7) 48 (70.6) 23 (48.9)* 67 (61.5) 4 (66.7) 55 (60.4) 16 (66.7) 61 (58.1) 10 (10 * 63 (58.9) 18 (100)* 61 (64.2) 10 (50.0)
Constipation 53 (46.1) 32 (47.1) 21 (44.7) 51 (46.8) 2 (33.3) 40 (44.0) 13 (54.2) 49 (46.7) 4 (40.0 51 (47.7) 2 (25.0) 42 (44.2) 11 (55.0)
Mental
disturbance
49 (42.6) 37 (54.4)) 12 (25.5)** 45 (41.3) 4 (66.7) 32 (35.2) 17 (70.8)** 42 (40.0) 7 (70.0 47 (43.9) 2 (25.0) 42 (44.2) 7 (35.0)
Gastrointestinal
bleeding
48 (41.7) 31 (45.6) 17 (36.2) 47 (43.1) 1 (16.7) 39 (42.9) 9 (37.5) 39 (37.1) 9 (90.0 * 44 (41.1) 4 (50.0) 40 (42.1) 8 (40.0)
Abdominal
distension
44 (38.3) 35 (51.5) 9 (19.2)** 43 (39.5) 1 (16.7) 32 (35.2) 12 (50.0) 35 (33.3) 9 (90.0 * 39 (36.5) 5 (62.5) 36 (37.9) 8 (40.0)
Anorexia 45 (39.1) 36 (52.9) 9 (19.2)** 44 (40.4) 1 (16.7) 30 (33.0) 15 (62.5)** 41 (39.1) 4 (40.0 40 (37.4) 5 (62.5) 34 (35.8) 11 (55.0)
Pressure sore 38 (33.0) 20 (29.4) 18 (38.3) 36 (33.0) 2 (33.3) 32 (35.2) 6 (25.0) 36 (34.3) 2 (20.0 34 (31.8) 4 (50.0) 32 (33.7) 6 (30.0)
Diarrhea 29 (25.2) 19 (27.9) 10 (21.3) 27 (24.8) 2 (33.3) 23 (25.3) 6 (25.0) 25 (23.8) 4 (40.0 26 (24.3) 3 (37.5) 25 (26.3) 4 (20.0)
Pain 23 (20.0) 20 (29.4) 3 (6.4)** 23 (21.1) 0 (0) 16 (17.6) 7 (29.2) 17 (16.2) 6 (60.0 * 19 (17.8) 4 (50.0) 20 (21.1) 3 (15.0)
Nausea 20 (17.4) 16 (23.5) 4 (8.5)* 20 (18.4) 0 (0) 17 (18.7) 3 (12.5) 16 (15.2) 4 (40.0 19 (17.8) 4 (50.0)* 15 (15.8) 5 (25.0)
Seizure 18 (15.7) 11 (16.2) 7 (14.9) 16 (14.7) 2 (33.3) 12 (13.2) 6 (25.0) 17 (16.2) 1 (10.0 16 (15.0) 2 (25.0) 18 (18.9) 0 (0)*
Delirium 15 (13.0) 9 (13.2) 6 (12.8) 14 (12.8) 1 (16.7) 14 (15.4) 1 (4.2) 11 (10.5) 4 (40.0 14 (13.1) 1 (12.5) 13 (13.7) 2 (10.0)
Wound 14 (12.2) 8 (11.8) 6 (12.8) 13 (11.9) 1 (16.7) 12 (13.2) 2 (8.3) 14 (13.3) 0 (0) 13 (12.2) 1 (12.5) 10 (10.5) 4 (20.0)
Urinary retention 11 (9.6) 7 (10.5) 4 (8.5) 11 (10.1) 0 (0) 7 (7.8) 4 (16.7) 9 (8.6) 2 (20.0 11 (10.4) 0 (0) 10 (10.5) 1 (5.3)
Pruritus 11 (9.6) 9 (13.2) 2 (4.3) 11 (10.1) 0 (0) 9 (9.9) 2 (8.3) 9 (8.6) 2 (20.0 8 (7.5) 3 (37.5)* 9 (9.5) 2 (10.0)
Jaundice 10 (8.7) 9 (13.2) 1 (2.1)* 10 (9.2) 0 (0) 10 (11.0) 0 (0) 2 (1.9) 8 (80.0 * 10 (9.4) 0 (0) 9 (9.5) 1 (5.0)
Insomnia 9 (7.8) 9 (13.2) 0 (0)* 9 (8.3) 0 (0) 3 (3.3) 6 (25.0)** 7 (6.7) 2 (2.0) 9 (8.4) 0 (0) 8 (8.4) 1 (5.0)
Ascites 9 (7.8) 8 (11.8) 1 (2.1)* 9 (8.3) 0 (0) 9 (9.9) 0 (0) 1 (1.0) 8 (80.0 * 9 (8.4) 0 (0) 9 (9.5) 0 (0)
Dizziness 8 (7.0) 4 (5.9) 4 (8.5) 8 (7.3) 1 (7.1) 6 (6.6) 2 (8.3) 7 (6.7) 1 (10.0 8 (7.5) 0 (0) 7 (7.4) 1 (5.0)
Oral ulcer 8 (7.0) 4 (5.9) 4 (8.5) 8 (7.3) 0 (0) 7 (7.7) 1 (4.2) 7 (6.7) 1 (10.0 8 (7.5) 0 (0) 6 (6.3) 2 (10.0)
Hematuria 5 (4.3) 4 (5.9) 1 (2.1) 5 (4.6) 0 (0) 2 (2.2) 3 (12.5) 5 (4.8) 0 (0) 5 (4.7) 0 (0) 4 (4.2) 1 (5.0)
Dysphagia 4 (3.5) 1 (1.5) 3 (6.4) 4 (3.7) 0 (0) 3 (3.3) 1 (4.2) 4 (3.8) 0 (0) 4 (3.7) 0 (0) 4 (4.2) 0 (0)
Incontinence 2 (1.7) 1 (1.5) 1 (2.3) 2 (1.8) 0 (0) 1 (1.1) 1 (4.2) 2 (1.9) 0 (0) 2 (1.9) 0 (0) 2 (2.1) 0 (0)
Hiccups 1 (0.9) 1 (1.5) 0 (0) 1 (0.9) 0 (0) 0 (0) 1 (4.2) 1 (1.0) 0 (0) 1 (0.9) 0 (0) 1 (1.1) 0 (0)
Data were summarized as n (%) for each category and compared using the Pearson chi-square test, or Fisher exact test if any numbe in the cell was lower than 5.
* p< 0.05; ** p< 0.01.
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Figure 1 Cumulative survival rate of the 115 subjects who
received palliative care. The curve was observed to approxi-
mate to the KaplaneMeier survival curve. The estimated
median survival time was 37 days (95% confidence interval
0e86.7 days)
Palliative care for nonmalignant disease in Taiwan 413hospital. The overall 6-month survival rate for all patients
was 37.6%, the short survival time reflecting late referral to
palliative care. The course of disease varied between
patients with cancer and nonmalignant disease. Patients
with nonmalignant disease had a longer natural course of
illness because the underlying disease progressed more
slowly. These patients were older and had multiple co-
morbidities. The main causes of death in these patients
were either repeated acute exacerbations of the underlying
disease or acute complications such as infections or other
acute illness.27 We did not observe any significant differ-
ences in symptoms between those who survived and those
who died, but patients who died had a higher rate of
abdominal distension (49.3%) than surviving patients
(22.9%).
Accurate prediction of a 6-month survival timedthe
standard window of time for referral to hospice caredin
patients with nonmalignant disease is difficult, and leads
patients and families to hesitate about requesting such
care.1,28 This may be a missed opportunity for patients to
receive proper evaluation of their symptoms and be
referred to a hospice for comprehensive, appropriate end-
of-life care, which is an important reason behind having
a better understanding of the symptoms prevalent in pol-
ysymptomatic late-stage nonmalignant patients in Taiwan.
Another major barrier to promoting palliative care in
nonmalignant disease occurs because medical staff and
families do not consider chronic illness to be a terminalTable 5 Awareness of disease and prognosis of patients/family
Patients who signed a “Do Not Resuscitate” order
Awareness of disease diagnosis on the part of patients
Awareness of disease prognosis on the part of patients
Awareness of disease and prognosis on the part of family membedisease.29 Only 10% of patients in this study were referred
to palliative care by their primary physician. A recent study
of the willingness of junior physicians in Taiwan to provide
palliative care indicates that educational intervention
regarding end-of-life care is highly needed among health-
care personnel in our country.30
Because of prognostic uncertainty, we agree that pallia-
tive care referral should depend on the patient’s needs
rather than the estimated survival time.14 The short survival
times after referral in this study reflect late enrollment in
palliative care and indicate a significant opportunity to
improve access to palliative care for patients with nonma-
lignant disease in Taiwan.We believe that palliative care can
help more patients and their family members to calmly face
and be clearly aware of the diagnosis and prognosis of their
late-stage disease. Besides identifying characteristic end-
of-life symptoms in patients with nonmalignant disease in
order to help identify candidates for palliative care, the
benefits of palliative care have been demonstrated in two
important ways in this study: we observed an increase in the
number of patients who signed DNR consent forms and an
increase in patients’ and relatives’ understanding of their
diagnosis and prognosis.
The opportunity to provide hospice services or palliative
care rather than more aggressive end-of-life care is impor-
tant and should not be missed for patients who would
benefit. Services for a cohort of 242,530 cancer patients who
died between 2000 and 2006 were evaluated and were found
to have become increasingly aggressive in the patients’ last
month of life; however, cardiopulmonary resuscitation,
mechanical ventilation, and intubation decreased, while use
of hospice services increased.7 The authors concluded that
the quality of end-of-life care in Taiwan was inferior to that
recommended as a benchmark for not providing overly
aggressive care in the last days of life.
In the present study, we observed that no patient
received cardiopulmonary resuscitation, intubation, or
cardiac massage after being enrolled in hospice care, which
points to a need for higher awareness on the part of
medical personnel, patients, and their families of the
palliative care concept, which could be applied at the
appropriate time when characteristic symptoms leading to
the terminal common pathway became apparent. Knowl-
edge of the prevalence of common symptoms is necessary
to identify the patients who are in need of and could
benefit from palliative care.
Study limitations
Our study had several limitations. First, we did not recruit
a control group of patients who did not receive palliative
care. Second, we did not analyze the results of a survey ofbefore and after palliative care.
Before palliative
care
After the start of
palliative care
105 114
13 64
10 25
rs 66 114
414 Y.-S. Hung et al.patients’ and families’ satisfaction with hospice care.
Third, we did not compare our results with those of other
palliative care facilities in other hospitals in Taiwan or
elsewhere in eastern Asia. Future prospective studies are
necessary to address these limitations. In addition, future
research is needed to determine when patients with
nonmalignant disease approaching the end of life should
seek palliative care.
Conclusions
Patients with life-threatening nonmalignant disease are
polysymptomatic at the end of life, and this characteristic
should be taken into account in providing appropriate end-
of-life care in the same way as it is for cancer patients. The
four leading symptoms in our patient sample were fatigue,
fever, cough, and dyspnea, indicating their presence across
the five late-stage disease entities. Early identification of
these distressing symptoms is necessary to assist medical
staff in the selection of candidates for palliative care and
to provide early management and appropriate symptom
control for this patient population. Hospice care with good
symptom control is warranted for patients with late-stage
nonmalignant disease who need appropriate end-of-life
care. Education of medical personnel in the availability
and capabilities of palliative care, and in identifying
patients who may benefit, is warranted, as is the produc-
tion and distribution of patient education materials
regarding the benefits and availability of palliative care.
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